Search

Your search keyword '"Puissant, Alexandre"' showing total 9 results
Start Over Author "Puissant, Alexandre" Journal leukemia
9 results on '"Puissant, Alexandre"'

1. Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia

Author

Pardieu, Bryann, Pasanisi, Justine, Ling, Frank, Dal Bello, Reinaldo, Penneroux, Justine, Su, Angela, Joudinaud, Romane, Chat, Laureen, Wu, Hsin Chieh, Duchmann, Matthieu, Sodaro, Gaetano, Chauvel, Clémentine, Castelli, Florence A., Vasseur, Loic, Pacchiardi, Kim, Belloucif, Yannis, Laiguillon, Marie-Charlotte, Meduri, Eshwar, Vaganay, Camille, Alexe, Gabriela, Berrou, Jeannig, Benaksas, Chaima, Forget, Antoine, Braun, Thorsten, Gardin, Claude, Raffoux, Emmanuel, Clappier, Emmanuelle, Adès, Lionel, de Thé, Hugues, Fenaille, François, Huntly, Brian J., Stegmaier, Kimberly, Dombret, Hervé, Fenouille, Nina, Lobry, Camille, Puissant, Alexandre, and Itzykson, Raphael

Published
2022
Full Text
View/download PDF

3. RETRACTED ARTICLE: LAMP2 expression dictates azacytidine response and prognosis in MDS/AML

Author

Dubois, Alix, Furstoss, Nathan, Calleja, Anne, Zerhouni, Marwa, Cluzeau, Thomas, Savy, Coline, Marchetti, Sandrine, Hamouda, Mohamed Amine, Boulakirba, Sonia, Orange, François, Lacas-Gervais, Sandra, Karsenti, Jean-Michel, Mounier, Nicolas, Tamburini, Jérôme, Puissant, Alexandre, Luciano, Frederic, Jacquel, Arnaud, Auberger, Patrick, and Robert, Guillaume

Published
2019
Full Text
View/download PDF

5. Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia

Author

Ali, Ashfaq, Penneroux, Justine, Dal Bello, Jr, Reinaldo, Massé, Aline, Quentin, Samuel, Unnikrishnan, Ashwin, Hernandez, Lucie, Raffoux, Emmanuel, Ben Abdelali, Raouf, Renneville, Aline, Preudhomme, Claude, Pimanda, John, Dombret, Hervé, Soulier, Jean, Fenaux, Pierre, Clappier, Emmanuelle, Adès, Lionel, Puissant, Alexandre, and Itzykson, Raphael

Published
2018
Full Text
View/download PDF

6. Retraction Note: LAMP2 expression dictates azacytidine response and prognosis in MDS/AML

Author

Dubois, Alix, Furstoss, Nathan, Calleja, Anne, Zerhouni, Marwa, Cluzeau, Thomas, Savy, Coline, Marchetti, Sandrine, Hamouda, Mohamed Amine, Boulakirba, Sonia, Orange, François, Lacas-Gervais, Sandra, Karsenti, Jean-Michel, Mounier, Nicolas, Tamburini, Jérôme, Puissant, Alexandre, Luciano, Frederic, Jacquel, Arnaud, Auberger, Patrick, and Robert, Guillaume

Published
2020
Full Text
View/download PDF

7. Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy

Author

Pikman, Yana, primary, Ocasio-Martinez, Nicole, additional, Alexe, Gabriela, additional, Dimitrov, Boris, additional, Kitara, Samuel, additional, Diehl, Frances F., additional, Robichaud, Amanda L., additional, Conway, Amy Saur, additional, Ross, Linda, additional, Su, Angela, additional, Ling, Frank, additional, Qi, Jun, additional, Roti, Giovanni, additional, Lewis, Caroline A., additional, Puissant, Alexandre, additional, Vander Heiden, Matthew G., additional, and Stegmaier, Kimberly, additional

Published
2021
Full Text
View/download PDF

9. LAMP2 expression dictates azacytidine response and prognosis in MDS/AML.

Author

Dubois A, Furstoss N, Calleja A, Zerhouni M, Cluzeau T, Savy C, Marchetti S, Hamouda MA, Boulakirba S, Orange F, Lacas-Gervais S, Karsenti JM, Mounier N, Tamburini J, Puissant A, Luciano F, Jacquel A, Auberger P, and Robert G

Subjects
Aged, Aged, 80 and over, Apoptosis, Biomarkers, Tumor genetics, Cell Proliferation, Female, Follow-Up Studies, Humans, Leukemia, Myeloid, Acute drug therapy, Leukemia, Myeloid, Acute metabolism, Lysosomal-Associated Membrane Protein 2 genetics, Male, Middle Aged, Prognosis, Survival Rate, Tumor Cells, Cultured, Antimetabolites, Antineoplastic pharmacology, Azacitidine pharmacology, Biomarkers, Tumor metabolism, Gene Expression Regulation, Neoplastic drug effects, Leukemia, Myeloid, Acute pathology, Lysosomal-Associated Membrane Protein 2 metabolism
Abstract

Chaperone-mediated autophagy (CMA) is a highly selective form of autophagy. During CMA, the HSC70 chaperone carries target proteins endowed with a KFERQ-like motif to the lysosomal receptor LAMP2A, which then translocate them into lysosomes for degradation. In the present study, we scrutinized the mechanisms underlying the response and resistance to Azacytidine (Aza) in MDS/AML cell lines and bone marrow CD34 + blasts from MDS/AML patients. In engineered Aza-resistant MDS cell lines and some AML cell lines, we identified a profound defect in CMA linked to the absence of LAMP2A. LAMP2 deficiency was responsible for Aza resistance and hypersensitivity to lysosome and autophagy inhibitors. Accordingly, gain of function of LAMP2 in deficient cells or loss of function in LAMP2-expressing cells rendered them sensitive or resistant to Aza, respectively. A strict correlation was observed between the absence of LAMP2, resistance to Aza and sensitivity to lysosome inhibitors. Low levels of LAMP2 expression in CD34 + blasts from MDS/AML patients correlated with lack of sensitivity to Aza and were predictive of poor overall survival. We propose that CD34 + /LAMP2 Low patients at diagnosis or who become CD34 + /LAMP2 Low during the course of treatment with Aza might benefit from a lysosome inhibitor already used in the clinic.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results